(08.05.2024) The Swiss biotech industry showed remarkable resilience in 2023. The sector boasted a revenue of 7.3 billion francs, nearly half a billion more than in 2022 (+7.35%). Moreover, it raised a record-breaking sum of 2 billion francs (+50% year-on-year).
In 2023, publicly traded companies secured the lion’s share of investments in the Swiss biotechnology industry, securing nearly 1.4 billion francs. Meanwhile, privately held firms managed to raise 600 million francs.
Most of the fundraising through stock markets was accomplished by firms MoonLake (415 million francs) and Oculis (144 million dollars). Meanwhile, companies like Noema Pharma (103 million francs), Alentis Therapeutics (94 million francs), Rejuveron (67 million francs), Nouscom (65 million francs), and NewBiologix (45 million francs) were among the primary beneficiaries of non-stock exchange investments.
In accordance with the global trend, companies on the stock markets have reduced their investments in research and development (R&D). However, their counterparts in private financing have nevertheless strengthened their cash reserves, while also increasing resources allocated to R&D activities.
The strong performance in the 2023 fiscal year is largely attributed to a rise in product sales, driven by a record number of approvals from competent authorities (SwissMedic, EMA, FDA etc.), including cutting-edge therapies from companies like CRISPR Therapeutics, Santhera, Idorsia, Relief Therapeutics, and Basilea.
Furthermore, the biotech industry experienced a surge in mergers and acquisitions (M&A) activity in 2023, involving both startups and established companies. Notable transactions included the acquisitions of Vertical Bio by Pierre Fabre, as well as VectivBio by Ironwood Pharma for 1 billion dollars.
Information
Last modification 08.05.2024
